Reunion Doses First Patient in Phase 2 Cancer Trial
Reunion Neuroscience’s RECONNECT Phase 2 trial in postpartum depression met its primary endpoint with a clinically meaningful reduction in...
Kynexis Doses First Patient in Phase 2 Schizophrenia Trial
Phase 1 data for KYN-5356 showed an acceptable safety and tolerability profile, adequate CNS penetration, dose-dependent reductions of kynurenic...
Positive Data in Eupraxia’s Highest-Dose Esophagitis Trial
Early signals from the highest planned dose in Eupraxia’s RESOLVE study point to stronger efficacy without new safety concerns....
Abivax ABTECT Phase 3 Trial Data Accepted at UEG Meeting
No numerical results were disclosed, but Abivax said its two Phase 3, 8‑week induction trials in moderately to severely...
Pivotal Ziftomenib AML Trial Launches, Doses First Patient
No new efficacy data were disclosed. The registrational Phase 3 program will test ziftomenib in two frontline settings with...
Promising Dyne Drug for Duchenne Gets Rare Japan Status
Dyne’s Phase 1/2 DELIVER trial of DYNE-251 has selected a registrational dose of 20 mg/kg administered every four weeks...
Cormedix Completes Enrollment for Phase III Rezzayo Trial
Enrollment is complete in the global Phase III ReSPECT study testing once‑weekly rezafungin for prophylaxis of Candida, Aspergillus, and...
Positive Interim Phase 2 Data for Artelo’s ART27.13 Drug
Interim data from the Phase 2 CAReS trial showed that patients titrated to the highest dose of ART27.13 (1,300...
New Phase 3 Data for CAN-2409 in Prostate Cancer at ASTRO
CAN-2409 improved disease-free survival by 30% versus placebo in a 745-patient Phase 3 trial in intermediate-to-high-risk localized prostate cancer...
Pioneering Pancreatic Cancer Trial Launched by Elicio, MSK
Updated Phase 1 data from Elicio’s AMPLIFY-201 program reported a 16.3-month median recurrence-free survival and 28.9-month median overall survival...